A Look at the Phase II SAGA Data for Gildeuretinol in Geographic Atrophy

(MedPage Today) — An oral investigational agent, gildeuretinol (ALK-001), demonstrated a significant reduction in geographic atrophy (GA) lesion growth and improvements in low luminance visual function in the phase II SAGA trial, according to…

Source link : https://www.medpagetoday.com/meetingcoverage/arvovideopearls/115716

Author :

Publish date : 2025-05-22 15:58:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

A Look at the Phase II SAGA Data for Gildeuretinol in Geographic Atrophy

AI Passes Gastro Board Exam; ALD Hospitalizations Surge; Post-Colonoscopy CRCs

Special contact lenses let you see infrared light – even in the dark

Related Posts

Being a Black Man in Medical School Takes a Toll

Ukrainian Trauma Surgeon: ‘Our Country Is Profoundly Exhausted’

Drug-Free Remission Remains Out of Reach for Most Axial Spondyloarthritis Patients

How to keep your yourself and your home cool in hot weather

Genetics or Microenvironment: What Drives CLL Progression?

Older Adults in the U.S. Are Increasingly Dying From Unintentional Falls

Being a Black Man in Medical School Takes a Toll

Ukrainian Trauma Surgeon: ‘Our Country Is Profoundly Exhausted’

Drug-Free Remission Remains Out of Reach for Most Axial Spondyloarthritis Patients

How to keep your yourself and your home cool in hot weather

Genetics or Microenvironment: What Drives CLL Progression?

Older Adults in the U.S. Are Increasingly Dying From Unintentional Falls

Women Survive Longer Than Men After Coronary Bypass

Shaping the Microbiome to Improve Cancer Immunotherapy

Categories

Archives